Print

AVEG 007A/B

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Two Dose Levels of SF-2 gp120 with or without MTP-PE Adjuvant in the M59 Emulsion

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) December 31, 1991
rgp120/HIV-1 SF-2 Env gp120 B SF-2
rgp120/HIV-1 SF-2 Protein
MTP-PE/MF59 Adjuvant Emulsion
USA 49
NCT00001019
https://clinicaltrials.gov/show/NCT00001019